Jerry O Stern

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. ncbi A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients
    Jerry O Stern
    Boehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    J Acquir Immune Defic Syndr 34:S21-33. 2003
  2. ncbi Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors
    Douglas T Dieterich
    Department of Medicine, Mt Sinai Medical Center, New York, New York 10029, USA
    Clin Infect Dis 38:S80-9. 2004

Collaborators

Detail Information

Publications2

  1. ncbi A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients
    Jerry O Stern
    Boehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    J Acquir Immune Defic Syndr 34:S21-33. 2003
    ..Use of nevirapine was not associated with a significantly increased risk of clinical hepatotoxic events, including liver failure or liver related death, compared to therapy with other antiretroviral drugs...
  2. ncbi Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors
    Douglas T Dieterich
    Department of Medicine, Mt Sinai Medical Center, New York, New York 10029, USA
    Clin Infect Dis 38:S80-9. 2004
    ..3% of nevirapine-treated patients) of these elevations were asymptomatic. Symptomatic hepatic events were seen in 4.9% (3.2%-8.9%) of nevirapine-treated patients...